SCHEMBL17471012

SCHEMBL17471012

C#COCc1ccc(C(N)C(=O)O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.40
CYP2C9 P11712 5/20 0.40
TDP1 Q9NUW8 4/20 0.40
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
CYP2C19 P33261 3/20 0.40
CYP2D6 P10635 2/20 0.40
GRM8 O00222 1/20 0.40
GRM6 O15303 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
DRD3 P35462 1/20 0.40
GRM4 Q14833 1/20 0.40
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 4/20 0.38
HPGD P15428 4/20 0.38
GRM1 Q13255 3/20 0.38
GRM2 Q14416 2/20 0.38
SLC7A5 Q01650 1/20 0.38
SLC1A1 P43005 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5327902 0.78 CYP2C9 (0.43) HSD17B10CYP2C9TDP1MEN1KMT2A
SCHEMBL4267584 0.75 HSD17B10 (0.43) HSD17B10CYP2C9TDP1MEN1KMT2A
SCHEMBL13527786 0.74 HSD17B10 (0.61) HSD17B10CYP2C9TDP1MEN1KMT2A
SCHEMBL8495584 0.73 HSD17B10 (0.48) HSD17B10CYP2C9TDP1MEN1KMT2A
SCHEMBL5279281 0.73 HSD17B10 (0.48) HSD17B10CYP2C9TDP1MEN1KMT2A
SCHEMBL34468380 0.73 HSD17B10 (0.48) HSD17B10CYP2C9TDP1MEN1KMT2A
SCHEMBL9782030 0.73 HSD17B10 (0.44) HSD17B10CYP2C9TDP1MEN1KMT2A
SCHEMBL8381292 0.72 ANPEP (0.53) HSD17B10CYP2C9TDP1MEN1KMT2A
SCHEMBL21433092 0.72 ALDH1A1 (0.50) HSD17B10CYP2C9TDP1MEN1KMT2A
SCHEMBL8669170 0.72 ANPEP (0.53) HSD17B10CYP2C9TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160022846-A1 IODINE RADIOLABELLING METHOD GE HEALTHCARE LTD (GB) 2016-01-28 US disclosed
US-20160022846-A1 IODINE RADIOLABELLING METHOD GE HEALTHCARE LTD (GB) 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022846-A1 IODINE RADIOLABELLING METHOD BTD, BTN3A1, BTF3 HSD17B10 2932/4885CYP2C9 4641/4885TDP1 3625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.